Plant Name: Uncaria gambir
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CXCR1; NPSR1; | |
| DRD4; | |
| RECQL; ALPL; TDP1; PLA2G1B; PIK3R1; GLO1; HPGD; MPO; AKR1B1; HSD17B2; ALOX12; NOX4; ALOX15; ALDH1A1; HSD17B10; PYGL; APEX1; POLB; | |
| GAA; | |
| DAPK1; AKT1; CAMK2B; MET; FLT3; NEK6; CDK1; PIM1; NEK2; AXL; NUAK1; ALK; KDR; GSK3B; SRC; PTK2; IGF1R; AURKB; PKN1; CSNK2A1; | |
| CA2; CA12; CA1; CA9; CA5A; CA5B; CA3; CA7; CA4; CA6; CA14; | |
| ALOX5; MAOA; XDH; | |
| KDM4E; | |
| BACE1; | |
| MMP13; MMP3; MMP2; MMP9; | |
| HIF1A; TP53; NFKB1; STAT6; | |
| FUT7; | |
| ABCG2; ABCC1; | |
| LMNA; MAPT; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005524; ATP binding | 3.247E-10 | 1.386E-07 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.407E-10 | 1.426E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.334E-10 | 2.112E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.891E-10 | 3.123E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.300E-09 | 6.679E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, MPO, NOX4, SRC |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 3.016E-08 | 7.062E-06 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.072E-08 | 1.093E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.249E-07 | 2.407E-05 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, GLO1, MMP13, MMP2, MMP3, MMP9, TP53 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.476E-07 | 2.794E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.659E-07 | 3.088E-05 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.526E-07 | 4.298E-05 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 3.375E-07 | 5.364E-05 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, NEK6, PKN1, SRC |
| BP | GO:0032502; developmental process | GO:0007568; aging | 3.814E-07 | 5.933E-05 | AKT1, APEX1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 4.315E-07 | 6.480E-05 | ALOX12, ALOX15, ALOX5, HPGD |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 6.298E-07 | 9.142E-05 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 7.270E-07 | 1.035E-04 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, PKN1 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.256E-06 | 1.638E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.397E-06 | 1.790E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.693E-06 | 3.294E-04 | AXL, MET, NOX4, PIK3R1, PTK2, SRC, THPO |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 4.415E-06 | 5.007E-04 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 4.923E-06 | 5.469E-04 | ABCC1, ABCG2, AKT1, ALK, ALOX12, ALOX15, ALPL, AXL, BACE1, CA12, CA14, CA2, CA4, CA9, CAMK2B, CSNK2A1, CXCR1, DAPK1, DRD4, FLT3, GAA, GLO1, GSK3B, HSD17B10, IGF1R, KDR, MAPT, MET, MMP2, NPSR1, PIK3R1, PIM1, PKN1, PTK2, SRC, TDP1 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 8.118E-06 | 8.581E-04 | CSNK2A1, HIF1A, KDR, MAPT |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.068E-05 | 1.092E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 1.143E-05 | 1.147E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.180E-05 | 1.168E-03 | AKT1, ALPL, APEX1, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4, SRC |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.358E-05 | 1.296E-03 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.358E-05 | 1.296E-03 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 1.591E-05 | 1.461E-03 | ALPL, AXL, CYP1A1, CYP1A2, HPGD, MPO, NFKB1, SRC |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.610E-05 | 1.461E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.610E-05 | 1.461E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.610E-05 | 1.461E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.905E-05 | 1.672E-03 | ABCG2, AKT1, ALK, CAMK2B, CSNK2A1, DAPK1, DRD4, FLT3, HPGD, IGF1R, KDR, MAPT, MET, MMP9, NFKB1, PYGL, STAT6, TP53, XDH |
| MF | GO:0005488; binding | GO:0008134; transcription factor binding | 2.394E-05 | 2.033E-03 | APEX1, FLT3, GSK3B, HIF1A, NEK6, NFKB1, PIK3R1, PIM1, PKN1, SRC, TP53 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.544E-05 | 2.147E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 3.152E-05 | 2.562E-03 | AKT1, CYP1B1, DAPK1, GSK3B, HPGD, MAPT, MMP9, NOX4, SRC, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 3.170E-05 | 2.566E-03 | AKT1, MAPT, NOX4, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 3.232E-05 | 2.607E-03 | AKT1, LMNA, MMP9, TP53 |
| CC | GO:0043226; organelle | GO:0043227; membrane-bounded organelle | 3.395E-05 | 2.708E-03 | ABCC1, ABCG2, AKR1B1, AKT1, ALDH1A1, ALK, ALOX12, ALPL, APEX1, AURKB, AXL, BACE1, CA1, CA2, CA4, CA5A, CA5B, CA6, CDK1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, FLT3, FUT7, GAA, GLO1, GSK3B, HIF1A, HPGD, HSD17B10, IGF1R, KDM4E, KDR, LMNA, MAOA, MAPT, MMP2, MMP9, MPO, NEK6, NFKB1, NOX4, NUAK1, PIK3R1, PIM1, PKN1, PLA2G1B, POLB, PTK2, PYGL, RECQL, SRC, TDP1, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 3.471E-05 | 2.749E-03 | ALOX15, GSK3B, MAPT, MET, MMP3, SRC, TP53 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.571E-05 | 2.817E-03 | AURKB, CA2, CA7, HIF1A, NEK2, NPSR1, PLA2G1B |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 3.792E-05 | 2.981E-03 | AKT1, ALOX12, AXL, CA2, CAMK2B, CDK1, CYP1B1, HIF1A, KDR, LMNA, MAPT, NFKB1, PIM1, SRC, STAT6, THPO |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 3.846E-05 | 3.012E-03 | IGF1R, KDR, PTK2, SRC |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 4.135E-05 | 3.193E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.817E-05 | 3.604E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.817E-05 | 3.604E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.817E-05 | 3.604E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.817E-05 | 3.604E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 4.844E-05 | 3.612E-03 | AKT1, APEX1, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, GSK3B, HSD17B10, MAOA, MMP2, MPO, NFKB1, NOX4, SRC, TP53 |
| BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 6.061E-05 | 4.414E-03 | GSK3B, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 6.348E-05 | 4.607E-03 | AKT1, HIF1A, LMNA, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0005977; glycogen metabolic process | 6.675E-05 | 4.797E-03 | AKT1, GAA, GSK3B, PYGL |
| BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 6.788E-05 | 4.851E-03 | AKR1B1, ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP3A4, MPO, PLA2G1B |
| BP | GO:0051179; localization | GO:0046903; secretion | 6.794E-05 | 4.851E-03 | ALOX5, AXL, CA2, CA9, CXCR1, DRD4, GAA, HIF1A, MMP9, MPO, NFKB1, PLA2G1B, PYGL, XDH |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 7.471E-05 | 5.197E-03 | AKR1B1, ALOX12, ALOX15, CSNK2A1, CYP19A1, CYP1A1, CYP3A4, HSD17B2, PIK3R1, PLA2G1B |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 7.598E-05 | 5.269E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 7.995E-05 | 5.474E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 9.205E-05 | 6.222E-03 | AKT1, ALOX15, AXL, DAPK1, FLT3, GSK3B, HIF1A, NFKB1 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 9.230E-05 | 6.222E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 9.608E-05 | 6.418E-03 | CYP1A1, CYP1A2 |
| BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 9.820E-05 | 6.499E-03 | ALOX15, ALPL, MMP13, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.058E-04 | 6.984E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 1.066E-04 | 6.993E-03 | AXL, FLT3, HIF1A, PKN1, POLB |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 1.066E-04 | 6.993E-03 | CA3, CDK1, HPGD, POLB, TP53 |
| BP | GO:0051179; localization | GO:0051050; positive regulation of transport | 1.211E-04 | 7.777E-03 | AKT1, AXL, CA2, CDK1, CYP19A1, DRD4, GSK3B, HIF1A, NPSR1, PIK3R1, PLA2G1B, SRC, TP53 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.236E-04 | 7.914E-03 | AURKB, CA2, CA7, HIF1A, KDR, NEK2, NPSR1, PLA2G1B, SRC |
| BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 1.301E-04 | 8.233E-03 | AKT1, KDR, MAPT, SRC |
| BP | GO:0008152; metabolic process | GO:2000573; positive regulation of DNA biosynthetic process | 1.301E-04 | 8.233E-03 | AURKB, NEK2, NOX4, SRC |
| BP | GO:0002376; immune system process | GO:0045321; leukocyte activation | 1.351E-04 | 8.527E-03 | ALOX5, AXL, CXCR1, FLT3, FUT7, GAA, MAPT, MMP9, MPO, NFKB1, PIK3R1, PYGL |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 1.382E-04 | 8.671E-03 | MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.540E-04 | 9.448E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.597E-04 | 9.661E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 1.647E-04 | 9.906E-03 | AKT1, HIF1A, NFKB1, SRC |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.005E-24 | 3.271E-20 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.539E-17 | 6.703E-14 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.480E-16 | 4.029E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.847E-23 | 3.306E-21 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.084E-11 | 1.866E-09 | CAMK2B; SRC; MMP2; KDR; AKT1; PIK3R1; TP53; HIF1A; MMP9; MET; PTK2; IGF1R |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 4.192E-09 | 1.876E-07 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AKT1; MET; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.012E-09 | 1.200E-07 | HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.011E-08 | 1.436E-06 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.967E-07 | 4.400E-06 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP3A4; CYP19A1; HSD17B10; CYP2C8; FUT7; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; ALPL; XDH |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 8.195E-07 | 1.334E-05 | GSK3B; KDR; AKT1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; IGF1R |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 9.967E-08 | 2.549E-06 | CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.390E-07 | 4.754E-06 | FLT3; AKT1; PIK3R1; TP53; MET; HIF1A |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.743E-08 | 2.549E-06 | CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.207E-06 | 1.661E-05 | GSK3B; SRC; KDR; AKT1; PIK3R1; MET; PTK2; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.300E-06 | 1.663E-05 | GSK3B; AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.137E-06 | 1.661E-05 | CAMK2B; GSK3B; SRC; AKT1; PIK3R1; PTK2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.319E-07 | 9.522E-06 | DAPK1; SRC; MMP2; MMP9; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.638E-06 | 1.955E-05 | SRC; AKT1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.831E-06 | 3.167E-05 | FLT3; PIM1; AKT1; PIK3R1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.064E-06 | 3.227E-05 | CAMK2B; AKT1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 3.974E-06 | 3.952E-05 | SRC; KDR; AKT1; PIK3R1; PTK2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 5.451E-06 | 4.646E-05 | CAMK2B; AKT1; PIK3R1; TP53; IGF1R |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 8.425E-06 | 6.040E-05 | GSK3B; CXCR1; SRC; AKT1; PIK3R1; NFKB1; PTK2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.309E-06 | 4.060E-05 | CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 6.743E-06 | 5.486E-05 | GSK3B; SRC; AKT1; PIK3R1; TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 7.429E-06 | 5.782E-05 | CAMK2B; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.392E-05 | 9.228E-05 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.451E-06 | 4.646E-05 | CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 8.436E-06 | 6.040E-05 | AKT1; PIK3R1; TP53; MET; IGF1R |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 9.039E-06 | 6.223E-05 | GSK3B; SRC; AKT1; PIK3R1; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.521E-05 | 9.726E-05 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 2.949E-05 | 1.650E-04 | PLA2G1B; KDR; AKT1; PIK3R1; MET; NFKB1; IGF1R |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 4.686E-05 | 2.396E-04 | MMP2; PIM1; AKT1; PIK3R1; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.317E-05 | 1.799E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.156E-05 | 1.245E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.257E-05 | 2.241E-04 | SRC; MMP2; AKT1; PIK3R1; MMP9 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.710E-05 | 1.049E-04 | CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.045E-05 | 3.234E-04 | MMP3; AKT1; PIK3R1; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 6.745E-05 | 3.177E-04 | GSK3B; AKT1; PIK3R1; PYGL; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 7.676E-05 | 3.435E-04 | CYP2C8; MAOA; ALOX5; ALOX15; ALOX12 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.499E-04 | 5.577E-04 | POLB; SRC; CDK1; PIK3R1; TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.064E-04 | 4.536E-04 | ABCC1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.592E-04 | 5.701E-04 | ABCC1; PIM1; CYP1B1; TP53; MMP9; MET; NFKB1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.753E-04 | 6.035E-04 | SRC; KDR; AKT1; PIK3R1; MET; IGF1R |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.496E-04 | 5.577E-04 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.740E-05 | 3.177E-04 | ALK; AKT1; PIK3R1; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 5.027E-05 | 2.500E-04 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.726E-04 | 6.035E-04 | GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.192E-04 | 6.883E-04 | LMNA; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.006E-04 | 4.391E-04 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.284E-04 | 5.224E-04 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.284E-04 | 5.224E-04 | AKT1; PIK3R1; MET; HIF1A |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.758E-05 | 1.049E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 3.832E-04 | 1.162E-03 | THPO; PIM1; AKT1; STAT6; PIK3R1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 5.139E-04 | 1.533E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.442E-04 | 5.577E-04 | CXCR1; SRC; MET; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.900E-04 | 6.183E-04 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 5.857E-04 | 1.691E-03 | CDK1; AKT1; PIK3R1; IGF1R |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 5.857E-04 | 1.691E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.900E-04 | 6.183E-04 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.527E-04 | 5.577E-04 | CYP2C8; MAOA; CYP1A2; CYP3A4 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 7.325E-04 | 2.081E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.173E-03 | 3.231E-03 | ALOX5; AKT1; PIK3R1; NFKB1 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 3.430E-03 | 8.409E-03 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.313E-03 | 5.916E-03 | GSK3B; AKT1; PIK3R1; IGF1R |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.313E-03 | 5.916E-03 | CAMK2B; GSK3B; CSNK2A1; TP53 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.141E-03 | 5.635E-03 | GSK3B; AKT1; PIK3R1; PYGL |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 2.889E-03 | 7.181E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.173E-03 | 3.231E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 3.780E-03 | 9.022E-03 | CXCR1; THPO; FLT3; KDR; MET |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.900E-04 | 6.183E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.002E-04 | 6.400E-04 | CSNK2A1; SRC; MET; IGF1R |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 2.453E-04 | 7.571E-04 | SRC; PIK3R1; MET; PTK2 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 4.885E-03 | 1.136E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 4.229E-03 | 9.960E-03 | BACE1; GSK3B; MAPT; HSD17B10 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 5.186E-03 | 1.190E-02 | CAMK2B; SRC; AKT1; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 5.937E-03 | 1.328E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 7.648E-03 | 1.592E-02 | CAMK2B; AKT1; PIK3R1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 5.419E-03 | 1.228E-02 | CAMK2B; SRC; MMP2 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 7.231E-03 | 1.541E-02 | AKT1; PIK3R1; HIF1A |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.209E-02 | 2.404E-02 | SRC; AKT1; PIK3R1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 7.035E-03 | 1.536E-02 | PIK3R1; NFKB1; PTK2 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 7.231E-03 | 1.541E-02 | CAMK2B; AKT1; PYGL |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 9.361E-03 | 1.883E-02 | CAMK2B; AKT1; PIK3R1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.235E-02 | 2.430E-02 | CAMK2B; CDK1; IGF1R |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 8.255E-03 | 1.679E-02 | AKT1; PIK3R1; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.765E-02 | 3.097E-02 | AKT1; MAPT; TP53; NFKB1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.263E-02 | 2.430E-02 | AKT1; PIK3R1; IGF1R |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 7.836E-03 | 1.612E-02 | AKT1; PIK3R1; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.263E-02 | 2.430E-02 | GSK3B; CDK1; TP53 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.492E-02 | 2.725E-02 | AKT1; PIK3R1; NFKB1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.522E-02 | 2.752E-02 | AKT1; PIK3R1; IGF1R |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 1.711E-02 | 3.032E-02 | CSNK2A1; SRC; AKT1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.878E-02 | 3.263E-02 | CXCR1; AKT1; PIK3R1 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.346E-02 | 2.510E-02 | GSK3B; MET; PTK2 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 2.017E-02 | 3.377E-02 | CAMK2B; AKT1; PIK3R1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 2.004E-03 | 5.353E-03 | AKT1; PIK3R1; IGF1R |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.391E-02 | 3.963E-02 | CAMK2B; SRC; PIK3R1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.664E-03 | 4.514E-03 | AKT1; PIK3R1; HIF1A |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.696E-03 | 6.796E-03 | CA2; CYP3A4; ABCG2 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 2.898E-02 | 4.631E-02 | AKT1; PIK3R1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 3.057E-02 | 4.800E-02 | AKT1; NFKB1 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 2.820E-02 | 4.547E-02 | CAMK2B; MAOA |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 2.977E-02 | 4.716E-02 | CDK1; TP53 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 2.666E-02 | 4.338E-02 | SRC; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 2.666E-02 | 4.338E-02 | STAT6; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.018E-02 | 3.377E-02 | AKT1; PIK3R1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.951E-02 | 3.358E-02 | GSK3B; TP53 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 2.018E-02 | 3.377E-02 | GAA; PYGL |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.569E-02 | 2.808E-02 | MAOA; NFKB1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.334E-02 | 2.510E-02 | AKT1; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.391E-02 | 2.567E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.278E-02 | 2.433E-02 | ABCC1; ABCG2 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 6.086E-03 | 1.345E-02 | GAA; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 7.331E-03 | 1.544E-02 | POLB; APEX1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.602E-03 | 8.714E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.490E-04 | 5.577E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; TP53; MMP9; KDR; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| NA: NA | Edema | NA | CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; AKT1; MMP2; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; CDK1; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; TP53; TP53; AURKB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; CYP3A4; MAOA |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; IGF1R |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; AKT1 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| NA: NA | GIST | NA | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP13; MPO; PLA2G1B; ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP13; MMP3; MMP2; ALOX5 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CYP19A1; CA9; CDK1; KDR; KDR; KDR; IGF1R |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; PTK2 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP3; CAMK2B; AKR1B1; PLA2G1B; ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Cancer | C00-C96 | FLT3; FLT3; AKT1; HIF1A; TP53; CA1; MET; CA9; CDK1; MMP9; NFKB1; SRC; PIM1; MMP2; KDR; GSK3B; PTK2; IGF1R; CSNK2A1 |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; SRC; AURKB |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; KDR; IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; AKT1; HIF1A; TP53; MET; CA9; MMP9; SRC; MMP2; KDR; KDR; KDR; PTK2; IGF1R; AURKB |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; ALOX5 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; HIF1A; CA9 |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; KDR; IGF1R; IGF1R |